sildenafil PAH
Selected indexed studies
- Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. (JAMA, 2022) [PMID:35412560]
- Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. (J Am Coll Cardiol, 2010) [PMID:20430262]
- New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review. (Cureus, 2024) [PMID:39347150]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. (2022) pubmed
- New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review. (2024) pubmed
- Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. (2010) pubmed
- miR-30d Attenuates Pulmonary Arterial Hypertension via Targeting MTDH and PDE5A and Modulates the Beneficial Effect of Sildenafil. (2024) pubmed
- Sildenafil in Infants and Children. (2017) pubmed
- Sildenafil for Pulmonary Arterial Hypertension. (2019) pubmed
- Egln1(Tie2Cre) Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1(Tie2Cre) Mice as a Useful PAH Model. (2023) pubmed
- Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH). (2017) pubmed
- Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension. (2024) pubmed
- Sildenafil in pediatric pulmonary arterial hypertension. (2015) pubmed